Abbonarsi

Epidemiology, risk factors and prognosis of ventilator-associated pneumonia during severe COVID-19: Multicenter observational study across 149 European Intensive Care Units - 18/01/23

Doi : 10.1016/j.accpm.2022.101184 
Marc Garnier a, , Jean-Michel Constantin b, Nicholas Heming c, d, e, Laurent Camous f, Alexis Ferré g, Keyvan Razazi h, i, Nathanaël Lapidus j

on behalf of the COVID-ICU Investigators1

  COVID-ICU Investigators are listed in Appendix A.

a Sorbonne University, GRC29, Assistance Publique-Hôpitaux de Paris (APHP), DMU DREAM, Anesthesiology and Critical Care Medicine Department, Tenon Hospital, Paris, France 
b Sorbonne University, GRC29, Assistance Publique-Hôpitaux de Paris (APHP), DMU DREAM, Anesthesiology and Critical Care Medicine Department, Pitié-Salpêtrière Hospital, Paris, France 
c Department of Intensive Care, Hôpital Raymond Poincaré, APHP University Versailles Saint Quentin — University Paris Saclay, France 
d Laboratory of Infection & Inflammation — U1173, School of Medicine Simone Veil, University Versailles Saint Quentin — University Paris Saclay, INSERM, Garches, France 
e FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis) & RHU RECORDS (Rapid rEcognition of CORticosteroiD resistant or sensitive Sepsis), Garches, France 
f Antilles-Guyane University, Medical and Surgical Intensive Care Unit, Guadeloupe Teaching Hospital, Les Abymes, France 
g Intensive Care Unit, Versailles Hospital, Le Chesnay, France 
h AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, F-94010 Créteil, France 
i Université Paris Est Créteil, Faculté de Médecine de Créteil, IMRB, GRC CARMAS, Créteil 94010, France 
j Sorbonne University, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Saint-Antoine Hospital, Public Health Department, F75012 Paris, France 

Corresponding author at: Anesthesiology and Critical Care Department, Tenon University Hospital, 4 Rue de la Chine, 75020 Paris, France.Anesthesiology and Critical Care DepartmentTenon University Hospital4 Rue de la ChineParis75020France

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

COVID-19 patients requiring mechanical ventilation are particularly at risk of developing ventilator-associated pneumonia (VAP). Risk factors and the prognostic impact of developing VAP during critical COVID-19 have not been fully documented.

Methods

Patients invasively ventilated for at least 48 h from the prospective multicentre COVID-ICU database were included in the analyses. Cause-specific Cox regression models were used to determine factors associated with the occurrence of VAP. Cox-regression multivariable models were used to determine VAP prognosis. Risk factors and the prognostic impact of early vs. late VAP, and Pseudomonas-related vs. non-Pseudomonas-related VAP were also determined.

Main findings

3388 patients were analysed (63 [55–70] years, 75.8% males). VAP occurred in 1523/3388 (45.5%) patients after 7 [5–9] days of ventilation. Identified bacteria were mainly Enterobacteriaceae followed by Staphylococcus aureus and Pseudomonas aeruginosa. VAP risk factors were male gender (Hazard Ratio (HR) 1.26, 95% Confidence Interval [1.09–1.46]), concomitant bacterial pneumonia at ICU admission (HR 1.36 [1.10–1.67]), PaO2/FiO2 ratio at intubation (HR 0.99 [0.98–0.99] per 10 mmHg increase), neuromuscular-blocking agents (HR 0.89 [0.76–0.998]), and corticosteroids (HR 1.27 [1.09–1.47]). VAP was associated with 90-mortality (HR 1.34 [1.16–1.55]), predominantly due to late VAP (HR 1.51 [1.26–1.81]). The impact of Pseudomonas-related and non-Pseudomonas-related VAP on mortality was similar.

Conclusion

VAP affected almost half of mechanically ventilated COVID-19 patients. Several risk factors have been identified, among which modifiable risk factors deserve further investigation. VAP had a specific negative impact on 90-day mortality, particularly when it occurred between the end of the first week and the third week of ventilation.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : COVID-19, Intensive Care Unit, Invasive mechanical ventilation, Mortality, Risk factors, Ventilator-associated pneumonia

Abbreviations : ARDS, C-VAP, COVID-19, HR, ICU, IL, IMV, NC-VAP, NMBA, VAP


Mappa


© 2022  Société française d'anesthésie et de réanimation (Sfar). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 42 - N° 1

Articolo 101184- Febbraio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • A new machine learning algorithm to predict veno-arterial ECMO implantation after post-cardiotomy low cardiac output syndrome
  • Louis Morisson, Baptiste Duceau, Hermann Do Rego, Aymeric Lancelot, Geoffroy Hariri, Ahmed Charfeddine, Pascal Laferrière-Langlois, Philippe Richebé, Guillaume Lebreton, Sophie Provenchère, Adrien Bouglé
| Articolo seguente Articolo seguente
  • Mesenteric traction syndrome — Incidence, impact, and treatment: A systematic scoping review of the literature
  • August A. Olsen, Laser A. Bazancir, Stig Dahl, Daisuke Fukumori, Hironari Shiwaku, Lars Bo Svendsen, Michael P. Achiam

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.